We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Rapid Saliva Tests as Good as PCR Tests for Diagnosing COVID-19 in Early Phase of Infection

By LabMedica International staff writers
Posted on 11 Nov 2021
Print article
Illustration
Illustration

Researchers investigating whether rapid antigen testing can be used on saliva instead of swabbing the nasal cavity have found that saliva can be good enough for diagnosing COVID-19 in the early phase of infection.

The study from Lund University (Lund, Sweden) aimed to find out if rapid COVID-19 tests using saliva could be easier alternatives to the common PCR tests which involve a nose and throat sample taken with a cotton swab - a procedure that is often unpleasant. Quick diagnostic tools are crucial in reducing the spread of COVID-19. Today, there are several different test methods to identify an ongoing infection. The PCR tests used in healthcare and most commercially available antigen tests are usually taken with swabs in the nasal cavity - a method that many find uncomfortable. Antigen tests are used as a complement to PCR testing when increased test capacity or rapid test results are required. However, there are also saliva tests.

In the current study, the researchers compared RT-PCR tests with saliva samples they collected from 44 patients. All 44 participants had confirmed COVID-19, and had to clear their throat before spitting. The results showed that coronavirus can be detected in both saliva and nasal cavity samples, but that the concentrations are slightly lower in saliva. The researchers also examined four different rapid antigen tests available on the market, to see how well they detect the virus in saliva samples. All four antigen tests were found to be relatively sensitive in detecting the virus early in the infection, as the virus concentration is higher at that point. Later in the infection, when the virus concentration is lower, the antigen tests were not sufficiently sensitive. The researchers believe that rapid saliva tests are a good alternative to standard PCR testing, and can also supplement these methods as screening needs increase.

“Although our study isn’t definitive, our results indicate that rapid tests using saliva might be good enough for diagnosing COVID-19 in the early phase of infection”, said Magnus Rasmussen, specialist in infectious disease medicine at Skåne University Hospital and professor at Lund University, who led the study.

“The advantage of a saliva-based rapid test is that you can easily take it at home in peace and quiet. For many, it can make a big difference. If infection occurs in, for example, primary school, the younger unvaccinated students can be screened more quickly with a saliva-based rapid test. For children, it is important that sampling is simple and without discomfort”, added Yang de Marinis, who is the first author of the study.

Related Links:
Lund University 

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.